Cambrex Corp. (NYSE:CBM) shares were down 1.5% during trading on Monday . The stock traded as low as $42.98 and last traded at $43.36, with a volume of 437,453 shares. The stock had previously closed at $44.02.

Separately, Zacks Investment Research upgraded Cambrex Corp. from a “hold” rating to a “strong-buy” rating and set a $56.00 price target on the stock in a report on Wednesday, May 4th.

The company has a market cap of $1.38 billion and a price-to-earnings ratio of 21.6646. The company has a 50-day moving average of $50.02 and a 200-day moving average of $46.91.

Cambrex Corp. (NYSE:CBM) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.68 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.59 by $0.09. The business had revenue of $118.22 million for the quarter, compared to analyst estimates of $114.85 million. The company’s revenue was up 10.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.63 EPS. Equities research analysts expect that Cambrex Corp. will post $2.56 earnings per share for the current year.

In related news, Director William B. Korb sold 4,142 shares of the company’s stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $52.47, for a total transaction of $217,330.74. Following the transaction, the director now owns 24,704 shares of the company’s stock, valued at $1,296,218.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William B. Korb sold 3,420 shares of the company’s stock in a transaction on Monday, July 11th. The stock was sold at an average price of $55.00, for a total value of $188,100.00. Following the transaction, the director now directly owns 23,982 shares in the company, valued at approximately $1,319,010. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Cambrex Corp. stock. Morgan Stanley raised its position in Cambrex Corp. (NYSE:CBM) by 27.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 323,861 shares of the company’s stock after buying an additional 70,585 shares during the period. Morgan Stanley owned approximately 1.03% of Cambrex Corp. worth $15,250,000 as of its most recent SEC filing.

Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.